

Tuberculosis profile: Viet Nam

Population 2021: 97 million

Estimates of TB burden*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	169 000 (109 000-241 000)	173 (112-247)
HIV-positive TB incidence	5 100 (3 300-7 400)	5.3 (3.4-7.5)
MDR/RR-TB incidence**	8 900 (5 400-12 000)	9.1 (5.5-13)
HIV-negative TB mortality	12 000 (8 700-16 000)	12 (8.9-17)
HIV-positive TB mortality	2 200 (1 600-2 900)	2.2 (1.6-3)

Estimated proportion of TB cases with MDR/RR-TB*, 2021

New cases	4.3% (4.1-4.5)
Previously treated cases	15% (14-16)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2021	46% (32-71)
TB patients facing catastrophic total costs, 2016	63% (58-67)
TB case fatality ratio (estimated mortality/estimated incidence), 2021	9% (5-13)

TB case notifications, 2021

Total new and relapse	77 657
- % tested with rapid diagnostics at time of diagnosis	96%
- % with known HIV status	82%
- % pulmonary	79%
- % bacteriologically confirmed [^]	77%
- % children aged 0-14 years	1%
- % women (aged ≥15 years)	29%
- % men (aged ≥15 years)	70%
Total cases notified	78 935

TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	1 945	3%
- on antiretroviral therapy	1 521	78%

Drug-resistant TB care**, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases [^]	89%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases [^]	93%
Laboratory-confirmed cases - MDR/RR-TB ^{^^}	2 640
Patients started on treatment - MDR/RR-TB ^{^^^}	2 524
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^{^^}	181
Patients started on treatment - pre-XDR-TB or XDR-TB ^{^^^}	170
MDR/RR-TB cases tested for resistance to any fluoroquinolone	239

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	91%	99 852
Previously treated cases, excluding relapse, registered in 2020	84%	1 853
HIV-positive TB cases registered in 2020	83%	2 751
MDR/RR-TB cases started on second-line treatment in 2019	74%	2 981
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019	61%	236


TB preventive treatment, 2021

% of HIV-positive people (newly enrolled in care) on preventive treatment	49%
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	13% (12-14)


Funding for TB

Funding for TB, 2021 (US\$ millions)	54
- % domestic funding	9.1%
- % international funding	91%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




HIV-negative TB mortality (Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2021



Cases attributable to five risk factors, 2021



Funding for TB (US\$ millions)



* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
** RR is TB resistant to rifampicin (R), MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
^ Calculated for pulmonary cases only
^^ Includes cases with unknown previous TB treatment history
^^^ Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed

Generated 2022-11-28 by the World Health Organization (<https://www.who.int/teams/global-tuberculosis-programme/data>)